XXXIX Congresso Brasileiro De Reumatologia 2022
DOI: 10.47660/cbr.2022.2148
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of the Use of Subcutaneous Medicines for Osteoporosis in Patients of a Tertiary Hospital

Abstract: BACKGROUNDOsteoporosis (OP) is the most prevalent skeletal disease and can increase the risk of fracture. Within the pharmacological arsenal available for the control of OP, there are some options for subcutaneous (SC) use, such as denosumab (DNS), teriparatide (TER) and romosozumab (ROM). Adherence and persistence to treatment with SC use are influenced by age, cognition, needle anxiety, fear of losing medication and availability of a caregiver. The aim of this study was to evaluate the profile of patients us… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles